Fate Therapeutics (FATE) EBT (2012 - 2026)
Fate Therapeutics' (FATE) quarterly EBT came in at -$147.7 million in Q1 2026, up 12.01% YoY from -$131.9 million in Q1 2025, and down 354.5% on a QoQ basis from -$32.5 million in Q4 2025.
Fate Therapeutics (FATE) EBT (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of EBT data on file, last reported at -$147.7 million in Q1 2026.
- Quarterly EBT rose 12.01% year-over-year to -$147.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$300.5 million (up 69.45% YoY) and the FY2025 annual result came in at -$524.7 million, up 5.48% from the prior year.
- EBT fell to -$147.7 million in Q1 2026, from -$32.5 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$32.5 million in Q4 2025 to a low of -$420.0 million in Q4 2024.
- A 5-year average of -$179.6 million and a median of -$155.3 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT tumbled 110.33% — and 2025, when it soared 92.26%.
- Tracing FATE's EBT over 5 years: stood at -$357.8 million in 2022, then decreased by 2.75% to -$367.6 million in 2023, then slipped by 14.24% to -$420.0 million in 2024, then soared by 92.26% to -$32.5 million in 2025, then plunged by 354.5% to -$147.7 million in 2026.
- The last three EBT figures came in at -$147.7 million (Q1 2026), -$32.5 million (Q4 2025), and -$75.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -147.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -147.72 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -75.29 Mn |
| Jun 30, 2025 | -44.97 Mn |
| Mar 31, 2025 | -167.88 Mn |
| Dec 31, 2024 | -419.96 Mn |
| Sep 30, 2024 | -199.90 Mn |
| Jun 30, 2024 | -195.91 Mn |
| Mar 31, 2024 | -104.14 Mn |
| Dec 31, 2023 | -367.62 Mn |
| Sep 30, 2023 | -213.12 Mn |
| Jun 30, 2023 | -122.00 Mn |
| Mar 31, 2023 | -90.96 Mn |
| Dec 31, 2022 | -357.79 Mn |
| Sep 30, 2022 | -155.28 Mn |
| Jun 30, 2022 | -267.67 Mn |
| Mar 31, 2022 | -90.06 Mn |
| Dec 31, 2021 | -295.89 Mn |
| Sep 30, 2021 | -241.90 Mn |
| Jun 30, 2021 | -127.26 Mn |